Medable introduced evidence from a Tufts Center for the Study of Drug Development analysis indicating its Clinical Monitoring Agent can improve clinical research monitor efficiency and potentially reduce development costs. The modeling benchmarked real-world oncology development data and assessed how automation could reduce documentation gaps and discrepancies across trial sites. The report is not yet peer-reviewed, but it reinforces an emerging playbook: AI tools that streamline trial operations rather than just analysis. Sponsors may reassess monitoring workflows, particularly when trial execution time and documentation quality become cost-critical constraints.